SCHEMBL234727

SCHEMBL234727

Cc1cc2ncc3cc(-c4ccc(O)cc4)c(Cl)nc3n2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.49
RAB9A P51151 7/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
HPGD P15428 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
TP53 P04637 3/20 0.49
POLB P06746 1/20 0.38
CYP1A2 P05177 2/20 0.36
HTT P42858 1/20 0.36
KDR P35968 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 4/20 0.34
LMNA P02545 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34
TSPO P30536 1/20 0.34
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238571 0.90 NPC1 (0.61) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL237892 0.88 RAB9A (0.49) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL235881 0.88 RAB9A (0.48) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL238551 0.87 NPC1 (0.41) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL238454 0.86 HTT (0.49) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL239177 0.86 NPC1 (0.47) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL237538 0.85 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL2755334 0.83 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL236385 0.83 DYRK3 (0.43) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL235500 0.82 KMT2A (0.40) NPC1RAB9ASMN1; SMN2HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.